Molgramostim Nebuliser solution 300 mcg ( DrugBank: Molgramostim )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 229 | 肺胞蛋白症（自己免疫性又は先天性） | 7 |
229. 肺胞蛋白症（自己免疫性又は先天性）
臨床試験数 : 43 / 薬物数 : 34 - (DrugBank : 8) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 14
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-004078-32-IT (EUCTR) | 16/05/2019 | 07/01/2019 | Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalation | AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS - IMPALA-EX | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 20.0;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Molgramostim Nebuliser solution 300 mcg INN or Proposed INN: MOLGRAMOSTIM | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 90 | Phase 3 | Netherlands;France;Greece;Denmark;Russian Federation;Israel;Germany;United Kingdom;Italy | ||
| 2 | EUCTR2017-004078-32-GR (EUCTR) | 05/06/2018 | 10/05/2018 | Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalation | AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS - IMPALA-EX | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 20.0;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Molgramostim Nebuliser solution 300 mcg INN or Proposed INN: MOLGRAMOSTIM | Savara ApS | NULL | Not Recruiting | Female: yes Male: yes | 90 | Phase 3 | France;Greece;Denmark;Russian Federation;Israel;Netherlands;Germany;United Kingdom;Italy | ||
| 3 | EUCTR2017-004078-32-GB (EUCTR) | 05/06/2018 | 01/02/2018 | Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalation | AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS - IMPALA-EX | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 20.0;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Molgramostim Nebuliser solution 300 mcg INN or Proposed INN: MOLGRAMOSTIM | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 90 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | France;Greece;Denmark;Russian Federation;Israel;Netherlands;Germany;Italy;United Kingdom | ||
| 4 | EUCTR2017-004078-32-DE (EUCTR) | 30/05/2018 | 18/12/2017 | Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalation | AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS - IMPALA-EX | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 20.0;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Molgramostim Nebuliser solution 300 mcg INN or Proposed INN: MOLGRAMOSTIM | Savara ApS | NULL | Not Recruiting | Female: yes Male: yes | 90 | Phase 3 | France;Greece;Denmark;Russian Federation;Israel;Netherlands;Germany;United Kingdom;Italy | ||
| 5 | EUCTR2017-004078-32-NL (EUCTR) | 08/05/2018 | 18/12/2017 | Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalation | AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS - IMPALA-EX | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 20.0;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Molgramostim Nebuliser solution 300 mcg INN or Proposed INN: MOLGRAMOSTIM | Savara ApS | NULL | Not Recruiting | Female: yes Male: yes | 90 | Phase 3 | France;Greece;Denmark;Russian Federation;Israel;Germany;Netherlands;United Kingdom;Italy | ||
| 6 | EUCTR2017-004078-32-FR (EUCTR) | 22/03/2018 | 18/12/2017 | Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalation | AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS - IMPALA-EX | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 20.0;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Molgramostim Nebuliser solution 300 mcg INN or Proposed INN: MOLGRAMOSTIM | Savara ApS | NULL | Not Recruiting | Female: yes Male: yes | 90 | Phase 3 | Denmark;Russian Federation;Israel;Netherlands;Germany;United Kingdom;Italy;France;Greece | ||
| 7 | EUCTR2017-004078-32-DK (EUCTR) | 06/02/2018 | 18/12/2017 | Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalation | AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS - IMPALA-EX | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 20.0;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Molgramostim Nebuliser solution 300 mcg INN or Proposed INN: MOLGRAMOSTIM | Savara ApS | NULL | Not Recruiting | Female: yes Male: yes | 90 | Phase 3 | France;Greece;Denmark;Russian Federation;Israel;Netherlands;Germany;United Kingdom;Italy |